BioCryst Pharmaceuticals Reports $263.9 Million Net Income, Achieves First Annual Profitability

BioCryst Pharmaceuticals Achieves Profitability Amid Strategic Shifts

BioCryst Pharmaceuticals, a global biotechnology company specializing in rare disease treatments, reported a net income of $263.9 million for the year ended December 31, 2025, marking its first annual profitability milestone. This financial turnaround is largely attributed to a significant increase in total revenues, which surged to $874.8 million compared to $450.7 million in the previous year. The revenue boost was primarily driven by a $244.0 million increase in license revenue, mainly from the $243.3 million license of intellectual property to Neopharmed, and a $168.7 million increase in ORLADEYO revenue, excluding revenues associated with the European ORLADEYO business, due to strong patient demand, price increases, and higher paid shipment rates.

The company underwent strategic changes, including the sale of its European ORLADEYO business to Neopharmed Gentili S.p.A. for $250 million in cash, plus customary purchase price adjustments of $4.5 million. This divestiture resulted in a $4.5 million decrease in revenues associated with the European ORLADEYO business. BioCryst also entered into a Loan Agreement with Blackstone for $400 million, using the proceeds to complete the merger with Astria Therapeutics, acquiring Astria's lead product candidate, navenibart. These strategic moves are aimed at leveraging BioCryst's commercial infrastructure and focusing on rare disease assets with near-term value creation.

Key operational developments included the FDA approval of an oral pellet formulation of ORLADEYO for prophylactic therapy in pediatric patients with HAE aged 2 to <12 years. The company also announced positive interim results from the ALPHA-SOLAR trial, showcasing sustained HAE attack suppression with navenibart administered every three and six months. Research and development expenses decreased to $166.1 million from $174.6 million, reflecting the discontinuation of the Factor D program and a reduction in research and development headcount. Selling, general, and administrative expenses increased to $348.6 million, driven by transaction-related costs and increased compensation expenses.

Looking ahead, BioCryst anticipates that the global commercial market for ORLADEYO has the potential to reach a global peak of $1 billion in annual net revenues. The company expects to report data from the clinical trial of BCX17725 for the treatment of Netherton syndrome in up to 12 patients by the end of 2026. BioCryst plans to seek strategic alternatives for STAR-0310 and a strategic partner for the development of avoralstat beyond Phase 1. The company's future performance will depend on the successful commercialization of its products, the progression of its product candidates, and its ability to manage costs and capital allocation effectively.